TY - JOUR
T1 - Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion.
AU - Garderet, Laurent
AU - Ziagkos, Dimitris
AU - Van Biezen, Anja
AU - Iacobelli, Simona
AU - Finke, Jürgen
AU - Maertens, Johan
AU - Volin, Liisa
AU - Ljungman, Per
AU - Chevallier, Patrice
AU - Passweg, Jakob
AU - Schaap, Nicolaas
AU - Beelen, Dietrich
AU - Nagler, Arnon
AU - Blaise, Didier
AU - Poiré, Xavier
AU - Yakoub-agha, Ibrahim
AU - Lenhoff, Stig
AU - Craddock, Charles
AU - Schots, Rik
AU - Rambaldi, Alessandro
AU - Sanz, Jaime
AU - Jindra, Pavel
AU - Mufti, Ghulam J.
AU - Robin, Marie
AU - Kröger, Nicolaus
PY - 2018/3
Y1 - 2018/3
N2 - The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.
AB - The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.
KW - MDS
KW - del (5q)
KW - Allogeneic stem cell transplantation
U2 - 10.1016/j.bbmt.2017.11.017
DO - 10.1016/j.bbmt.2017.11.017
M3 - Article
SN - 1083-8791
VL - 24
SP - 507
EP - 513
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 3
ER -